These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22618707)

  • 1. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
    Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
    Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR1 blockade and myeloma bone disease.
    Sebag M
    Blood; 2012 Aug; 120(7):1351-2. PubMed ID: 22899473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR1 as a target for multiple myeloma.
    Vallet S; Anderson KC
    Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
    Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
    Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
    Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
    Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
    Vallet S; Raje N; Ishitsuka K; Hideshima T; Podar K; Chhetri S; Pozzi S; Breitkreutz I; Kiziltepe T; Yasui H; Ocio EM; Shiraishi N; Jin J; Okawa Y; Ikeda H; Mukherjee S; Vaghela N; Cirstea D; Ladetto M; Boccadoro M; Anderson KC
    Blood; 2007 Nov; 110(10):3744-52. PubMed ID: 17715391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells.
    Pevida M; Lastra A; Meana Á; Hidalgo A; Baamonde A; Menéndez L
    Neuroscience; 2014 Feb; 259():113-25. PubMed ID: 24316469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
    Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
    Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
    Gilchrist A; Echeverria SL
    Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4.
    Ramos CD; Canetti C; Souto JT; Silva JS; Hogaboam CM; Ferreira SH; Cunha FQ
    J Leukoc Biol; 2005 Jul; 78(1):167-77. PubMed ID: 15831559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.
    Hoshino A; Iimura T; Ueha S; Hanada S; Maruoka Y; Mayahara M; Suzuki K; Imai T; Ito M; Manome Y; Yasuhara M; Kirino T; Yamaguchi A; Matsushima K; Yamamoto K
    J Biol Chem; 2010 Sep; 285(37):28826-37. PubMed ID: 20571024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
    Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
    Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
    Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
    Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
    Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
    Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.